IDEXX Laboratories, Inc. (NASDAQ:IDXX) VP Brian P. Mckeon sold 6,602 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $181.36, for a total transaction of $1,197,338.72. Following the sale, the vice president now directly owns 47,040 shares in the company, valued at $8,531,174.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded down $2.55 on Thursday, hitting $174.28. 346,911 shares of the company traded hands, compared to its average volume of 575,188. IDEXX Laboratories, Inc. has a 52-week low of $140.63 and a 52-week high of $198.73. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97. The firm has a market cap of $15,703.73, a P/E ratio of 59.32, a PEG ratio of 2.21 and a beta of 0.58.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The firm had revenue of $506.00 million during the quarter, compared to the consensus estimate of $490.51 million. During the same quarter in the prior year, the firm earned $0.58 EPS. The company’s revenue for the quarter was up 14.2% on a year-over-year basis. sell-side analysts expect that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.
Several research firms have recently issued reports on IDXX. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 target price on the stock in a research note on Monday. Bank of America increased their target price on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. Piper Jaffray Companies increased their target price on shares of IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 31st. Finally, Canaccord Genuity reissued a “buy” rating and set a $210.00 target price on shares of IDEXX Laboratories in a research note on Monday, January 29th. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. IDEXX Laboratories presently has an average rating of “Buy” and a consensus target price of $194.00.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.